News - Research

Filter

Current filters:

Research

Popular Filters

1 to 25 of 2445 results

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Hospira’s Retacrit effective in chemotherapy-induced anemia

Hospira’s Retacrit effective in chemotherapy-induced anemia

24-07-2014

USA-based Hospira, a leading provider of generic injectable drugs and infusion technologies, announced…

BiosimilarsErythropoiesis-stimulating agentsGenericsHematologyHospiraInfusion technologiesResearchRetacritUSA

Expert View: Has UK pharma lost its Euro-vision?

Expert View: Has UK pharma lost its Euro-vision?

23-07-2014

Former AstraZeneca serialization expert, Christoph Krähenbühl, demystifies the arguments around compliance…

EuropeEuropean UnionMarkets & MarketingMedicines verification infrastructurePharmaceuticalResearchUK

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

23-07-2014

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows…

Aarhus UniversityAnti-viralsBiotechnologyCelgene Corp.DenmarkHIVHIV/AIDSIsodaxResearchromidepsin

Biotron’s BIT225 reverses HIV-induced impairment of the immune system

23-07-2014

Australian viral disease specialist Biotron presented data at the 20th International AIDS Conference,…

Anti-viralsAntiretroviral drugAustraliaBiotechnologyBiotronBIT225HIVHIV/AIDSImmune systemResearch

Merck strengthens commitment to Chinese growth market

Merck strengthens commitment to Chinese growth market

23-07-2014

Germany’s Merck KGaA, a leading company for high-tech products in the pharmaceutical and chemical sectors,…

ChinaFinancialMerckMerck KGaAPharmaceuticalProductionResearch

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

22-07-2014

Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune…

AdvaxisADXS-HPVAstraZenecaBiotechnologyMedImmuneOncologyPapillomavirusResearchSweden

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

22-07-2014

Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights…

AustraliaBiotechnologyFinancialOncologyOsteosarcomaRegeneusResearchSarcoma

Tesamorelin, which reduces abdominal fat in HIV patients, may also reduce fat in liver

22-07-2014

The only drug to receive US Food and Drug Administration approval for reduction of the abdominal fat…

EgriftaEMD SeronoMerck KGaANephrology and HepatologyPharmaceuticalResearchtesamorelinTherapy for HIVUSA

Biosimilars market to hit $35 billion by 2020, research suggests

Biosimilars market to hit $35 billion by 2020, research suggests

22-07-2014

The global biosimilars market could reach $35 billion by 2020, rising from the $1.3 billion it was worth…

BiosimilarsResearch

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

21-07-2014

Cancer Research UK scientists have discovered how two genes – called MEK and MET – cause bowel cancer…

Colorectal cancerOncologyPharmaceuticalResearchUKUniversity Belfast

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

20-07-2014

Anglo-Swedish pharma major AstraZeneca on Friday revealed designs for its planned network of glass-walled…

AstraZenecaManagementPharmaceuticalResearchUK

Fast growth forecast for dengue vaccine market

Fast growth forecast for dengue vaccine market

18-07-2014

Among the five major pharmaceutical markets (5MM: Brazil, India, Mexico, Singapore and Thailand), Brazil…

Asia-PacificBrazilMarkets & MarketingMexicoPharmaceuticalResearchTropical diseases

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

17-07-2014

GlaxoSmithKline says that the Independent Data Monitoring Committee (IDMC) has recommended a Phase III…

BRAFdabrafenibGlobalGSKMetastatic cutaneous melanomaOncologyPharmaceuticalResearchtrametinibvemurafenib

1 to 25 of 2445 results

Back to top